Trial
NCT03506802
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
Novartis Pharmaceuticals
Condition
HLA-A*0201 Positive Cells Present
Intervention
18F-FHBG
Why stopped
No Participants Enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-24